KBD4466
KBD4466 is an orally active potent TLR7 and TLR8 inhibitor with IC50s of 0.9 nM and 2.8 nM, respectively. KBD4466 inhibits the expression of inflammatory cytokines IL-6 and IFN-α. KBD4466 improves disease progression and survival in the BXSB/MpJ mouse model of Systemic Lupus Erythematosus (SLE). KBD4466 can be used in the study of autoimmune diseases.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 3023713-87-0
- Formel: C24H23F3N6O
- Molecular Weight:468.47
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
TLR7 0.9 nM (IC50) |
TLR8 2.8 nM (IC50) |
IL-6 |
In Vitro
Parmacokinetics
| Species | Dose | Route | T1/2 | Cmax | AUC0-t | F |
|---|---|---|---|---|---|---|
| Mice | 10 mg/kg | p.o. | 3.6 h | 1297 ng/mL | 6247 ng·h/mL | 58 % |
| Rat | 5 mg/kg | p.o. | 5.1 h | 948 ng/mL | 7628 ng·h/mL | >99 % |
In Vivo
KBD4466 (Compound 19) (1 mg/kg, p.o., once) inhibits the production of IL-6 and IFN-α in R848 (HY-13740 )-challenged mouse model[1].
KBD4466 (10 mg/kg, p.o., once a day, 14 weeks) improves disease symptoms in the BXSB/MpJ mouse lupus model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:R848 (25 μg per mouse, i.p., 1 h, 4 h, 8 h, 16 h, 24 h after administration of compound 19)-challenged mouse (female C57BL/6 mice, 6-8 weeks old) model [1]
-
Dosage:1 mg/kg
-
Administration:p.o., once
-
Result:Inhibited the production of IL-6, with an inhibition rate of 99.4% at 1 hour, more than 50% at 16 hours, and more than 90% at 8 hours.
Inhibited the production of IFN-α, with an inhibition rate of 98% at 16 h, 69% at 24 h.
-
Animal Model:SLE model using BXSB/MpJ transgenic mice (female BXSB/MpJ mice, 7 weeks).[1]
-
Dosage:10 mg/kg
-
Administration:p.o., once a day, 14 weeks
-
Result:Improved survival rates ,the survival rate reached 100%.
Relieved splenomegaly and lymphadenopathy, and reduced plasma levels of autoantibodies, including anti-histone antibodies, anti-ribosomal P (anti-RiboP), and anti-double-stranded DNA (anti-dsDNA).
Reduced urine microalbumin (MALB), urine microalbumin to creatinine ratio (MALB/CREA), and urine total protein (UTP) levels.
Improved kidney swelling.
Chemical Information
-
CAS. Nr. 3023713-87-0
-
Molecular Weight 468.47
-
Formel C24H23F3N6O
-
SMILES
CN1CCC(C2=NN=C([C@]34CN(C[C@]3(C4)C(F)(F)F)C5=C6C=CC=NC6=C(C=C5)C#N)O2)CC1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)